← Back to Search

Electromagnetic Field Treatment

EMF Treatment for Chronic Spinal Cord Injury

N/A
Recruiting
Led By Gabi Zeilig, Ph.D.
Research Sponsored by BrainQ Technologies Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week -1, week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34
Awards & highlights
No Placebo-Only Group

Summary

This trial will study the effects of the BQ EMF treatment on subjects with chronic SCI who have stable GRASSP scores after a month of physical therapy.

Who is the study for?
This trial is for adults aged 18-75 with chronic cervical incomplete spinal cord injury, stable enough to follow directions and engage in physical therapy. They must have a specific strength score (5-35 on GRASSP) and be able to move their shoulders to a certain degree. Pregnant women or those with severe cognitive issues, drug addiction, excessive pain/spasticity, recent botulinum toxin treatments, epilepsy, or implanted electronic devices cannot participate.
What is being tested?
The study tests the safety and effectiveness of BQ EMF treatment on patients with chronic spinal cord injuries who are stable after a month of physical therapy. The focus is on whether this electromagnetic field treatment can improve motor functions as measured by the GRASSP strength score.
What are the potential side effects?
While not explicitly listed in the provided information, potential side effects may include discomfort at the site of application or other reactions related to electromagnetic field exposure; however these will be monitored throughout the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week -1, week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34
This trial's timeline: 3 weeks for screening, Varies for treatment, and week -1, week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline of treatment to end of treatment in the Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP - strength subscore)
Secondary study objectives
Capabilities of the Upper Extremity Test (CUE-T)
GRASSP (sensibility and prehension subscores)
GRASSP (strength subscores)
+6 more
Other study objectives
Assessment of device's Usability by user (Human factors and usability analysis)
Range of motion (ROM)
Rate of deviation of device user from expected input sequence (Human factors and usability analysis)
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (with PT run-in)Experimental Treatment1 Intervention
Treatment group, to receive BQ treatment with PT, after stability established in 4 week PT run-in period

Find a Location

Who is running the clinical trial?

Sheba Medical CenterOTHER_GOV
736 Previous Clinical Trials
2,840,519 Total Patients Enrolled
BrainQ Technologies Ltd.Lead Sponsor
3 Previous Clinical Trials
250 Total Patients Enrolled
The Miami Project to Cure ParalysisOTHER
5 Previous Clinical Trials
27 Total Patients Enrolled
Kessler Institute for RehabilitationIndustry Sponsor
22 Previous Clinical Trials
1,157 Total Patients Enrolled
Gabi Zeilig, Ph.D.Principal InvestigatorSheba Medical Center
Dalton Dietrich, Ph.D.Principal InvestigatorThe Miami Project to Cure Paralysis
Ghaith Androwis, Ph.D.Principal InvestigatorKessler Institute of Rehabilitation

Media Library

BQ 1.2 (Electromagnetic Field Treatment) Clinical Trial Eligibility Overview. Trial Name: NCT04050696 — N/A
Spinal Cord Injury Research Study Groups: Treatment (with PT run-in)
Spinal Cord Injury Clinical Trial 2023: BQ 1.2 Highlights & Side Effects. Trial Name: NCT04050696 — N/A
BQ 1.2 (Electromagnetic Field Treatment) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04050696 — N/A
~1 spots leftby Dec 2025